Scarica l'app Stockscreener
18.19
2.78%
-0.52
Precedente Chiudi:
$18.71
Aprire:
$18.76
Volume 24 ore:
392.13K
Relative Volume:
0.57
Capitalizzazione di mercato:
$1.15B
Reddito:
$10.00M
Utile/perdita netta:
$-425.15M
Rapporto P/E:
-1.9997
EPS:
-9.0964
Flusso di cassa netto:
$-210.48M
1 W Prestazione:
-1.25%
1M Prestazione:
-0.82%
6M Prestazione:
-50.69%
1 anno Prestazione:
+82.45%
Intervallo 1D:
$17.87
$19.43
Intervallo di 1 settimana:
$17.53
$20.87
Portata 52W:
$8.91
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Nome
Zenas Biopharma Inc
Settore
Industria
Telefono
857-271-2954
Indirizzo
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
18.19 | 1.18B | 10.00M | -425.15M | -210.48M | -9.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | Iniziato | Wedbush | Outperform |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
ZBIO: Obexelimab nears launch for IgG4-RD, with a robust neuro-immunology pipeline advancing - TradingView
Why is Zenas BioPharma stock rallying 9% today? By Investing.com - Investing.com Canada
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - The Manila Times
Zenas BioPharma (ZBIO) Revenue BreakdownMain Composition - Moomoo
Guggenheim Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
H.C. Wainwright reiterates Zenas Biopharma stock rating at buy By Investing.com - Investing.com Canada
Zenas BioPharma's Potential Autoimmune Disease Treatment Meets Primary, Secondary Endpoints in Phase 3 Study - Moomoo
Zenas BioPharma reports positive phase 3 trial results for obexelimab By Investing.com - Investing.com Nigeria
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medici - The Manila Times
Zenas BioPharma Reports Positive Efficacy Results from Phase 3 INDIGO Trial of Obexelimab in IgG4-Related Disease - Quiver Quantitative
Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints - TradingView
Autoimmune trial: obexelimab slashes IgG4 flare risk 56% - Stock Titan
A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness - Yahoo Finance
Assessing Zenas BioPharma (ZBIO) Valuation After A Strong Year And Recent Share Price Weakness - Sahm
Why is Zenas BioPharma (ZBIO) Surging? Decoding the Insider Confidence Signal - Kavout
Zenas BioPharma Submits BLA to FDA for Obexelimab to Treat IgG4-Related Disease - geneonline.com
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD - The Manila Times
Zenas BioPharma Announces Submission of Biologics License - GlobeNewswire
54,485,518 Common Stock of Zenas BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Zenas BioPharma Stock Slips as a June Catalyst Moves Into View - Bez Kabli
What Zenas BioPharma (ZBIO)'s First-in-Human Oral IL-17 Inhibitor Trial Means For Shareholders - Sahm
ZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substa - GuruFocus
Zenas BioPharma to present obexelimab trial data at EULAR congress - Investing.com UK
Zenas BioPharma to present obexelimab trial data at EULAR congress By Investing.com - Investing.com Nigeria
Why is Zenas Biopharma stock climbing today? By Investing.com - Investing.com Australia
Zenas BioPharma To Present INDIGO Phase 3 Data At EULAR 2026; Wedbush Sees $45 Target - RTTNews
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress - The Manila Times
Zenas BioPharma Announces Upcoming Presentation of Results - GlobeNewswire
Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing - Moomoo
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma CEO Leon Moulder Jr purchases $1.01m in common stock By Investing.com - Investing.com South Africa
Zenas BioPharma CEO Leon Moulder Jr purchases $1.01m in common stock - Investing.com Australia
Zenas BioPharma (ZBIO) CEO adds 60,000 shares in open-market buy - Stock Titan
Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment - TipRanks
Zenas BioPharma rises as CEO continues insider purchases - MSN
Assessing Zenas BioPharma (ZBIO) Valuation After Obexelimab Phase 3 Success And New IL-17 Program Progress - Sahm
Vanguard Group Inc. Acquires 290,307 Shares of Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma, Inc. Common Stock (NASDAQ: ZBIO) Stock Price, News & Analysis - Kalkine
ZBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $44 - GuruFocus
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $22 - Moomoo
ZBIO SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Zenas BioPharma Releases Q1 2026 Financial Results - AlphaStreet
Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss - Yahoo Finance
Zenas BioPharma 4Q Loss/Shr $1.46 >ZBIO - Moomoo
Zenas Biopharma Inc Azioni (ZBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zenas Biopharma Inc Azioni (ZBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
Apr 29 '26 |
Buy |
17.62 |
35,000 |
616,700 |
1,786,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Apr 28 '26 |
Buy |
18.02 |
25,000 |
450,500 |
1,751,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
18.63 |
3,768 |
70,198 |
426,736 |
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Buy |
20.00 |
150,000 |
3,000,000 |
2,359,025 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 31 '26 |
Buy |
19.31 |
34,000 |
656,540 |
1,726,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 30 '26 |
Buy |
18.23 |
20,000 |
364,600 |
1,692,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
20.00 |
75,000 |
1,500,000 |
422,968 |
| Lu Hongbo | Director |
Feb 11 '26 |
Buy |
22.50 |
25,985 |
584,662 |
347,968 |
| Allen Patricia L | Director |
Feb 12 '26 |
Buy |
24.85 |
15,700 |
390,088 |
15,700 |
| Allen Patricia L | Director |
Feb 13 '26 |
Buy |
26.36 |
4,160 |
109,658 |
19,860 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):